CN111773202B - Medical application of dendrophenol and anti-propionibacterium acnes medicine - Google Patents
Medical application of dendrophenol and anti-propionibacterium acnes medicine Download PDFInfo
- Publication number
- CN111773202B CN111773202B CN202010794889.0A CN202010794889A CN111773202B CN 111773202 B CN111773202 B CN 111773202B CN 202010794889 A CN202010794889 A CN 202010794889A CN 111773202 B CN111773202 B CN 111773202B
- Authority
- CN
- China
- Prior art keywords
- dendrophenol
- medicine
- propionibacterium acnes
- medical application
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a medicinal application of dendrophenol and a medicine for resisting propionibacterium acnes, wherein the dendrophenol is applied to the preparation of the medicine for resisting propionibacterium acnes, has no toxic or side effect on a human body, can be used as a conventional antibiotic medicine which is easy to relapse infection and generate drug resistance after replacement treatment in some aspects to become a clinically preferred medicine for resisting propionibacterium acnes, and has great application prospect.
Description
Technical Field
The invention relates to a medical application of dendrophenol and a medicine for resisting propionibacterium acnes, belonging to the technical field of medical biology.
Background
Currently, dendrophenol (Gigantol, CAS: 67884-30-4), a bibenzyl phenolic substance, is extracted from the root of dendrobe and is one of the medicinal effective components of dendrobe. The dendrophenol can inhibit the release of macrophage inflammatory factors of mice induced by bacterial lipopolysaccharide through a nuclear transcription factor NF-kB approach, and reduce the apoptosis of glomerular mesangial cells of the mice induced by high glucose. In a high-glucose-induced human retinal microvascular endothelial cell injury model, dendrophenol is found to reduce intracellular reactive oxygen species levels to protect injured endothelial cells. In a diabetic mouse model, the dendrobium polyphenol extract can play a role in resisting diabetes and complications by regulating the abundance of intestinal flora.
Acne is a common chronic inflammatory disease of hair follicles and sebaceous glands caused by various factors, and clinically appears as comedo, papule, pustule, nodule, cyst, scar and the like. Propionibacterium acnes is an anaerobic gram-positive bacterium that is considered to be the major pathogenic bacterium of acne. When sebum secretion is excessive or pores are blocked due to various reasons, propionibacterium acnes rapidly proliferate, which can decompose saturated fatty acids to produce a large amount of free fatty acids, thereby causing skin stress reactions, and bacteria such as staphylococcus can further aggravate skin tissue damage. The existing external medicine for treating acne comprises antibiotics and vitamin A acids, wherein the former has the problem of easy generation of drug resistance and the like, and the latter has certain irritation and potential teratogenesis risk, so that the exploration of external anti-acne medicines which have good safety and are difficult to resist drugs is particularly urgent.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides the medical application of the dendrophenol, which is applied to the preparation of the anti-propionibacterium acnes medicine, has no toxic or side effect on a human body, can be used as a conventional antibiotic medicine for replacing easily relapsing infection and easily generating drug resistance after treatment to become a clinically preferred anti-propionibacterium acnes medicine in some aspects, and has great application prospect.
In order to solve the technical problems, the technical scheme of the invention is as follows: a medicinal application of dendrophenol in preparing medicine for resisting Propionibacterium acnes is disclosed.
Further, it is used for inhibiting Staphylococcus aureus.
Further, it is used for inhibiting Escherichia coli.
The invention also provides a medicine for resisting the propionibacterium acnes, which comprises dendrophenol.
Furthermore, the anti-acne propionibacterium medicine is a dosage form prepared from dendrophenol and pharmaceutically acceptable auxiliary materials or excipients.
Furthermore, the anti-acne propionibacterium drug is a dosage form prepared by taking dendrophenol as an effective component and adding a bacteria inhibiting drug component and pharmaceutically acceptable auxiliary materials or excipients.
After the technical scheme is adopted, the dendrophenol has obvious antibacterial and bacteriostatic effects on propionibacterium acnes, staphylococcus aureus and escherichia coli, and can be used for preparing corresponding antibacterial drugs.
Drawings
FIG. 1 is a graph showing the results of the control group and the dendrobe phenol group for the respective bacteriostatic ring radii of Propionibacterium acnes, Staphylococcus aureus, or Escherichia coli; wherein the content of the first and second substances,* P <0.05 compared to control group;
FIG. 2: dendrophenol Minimum Inhibitory Concentration (MIC) determination result graph.
Detailed Description
In order that the present invention may be more readily and clearly understood, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments that are illustrated in the appended drawings.
Example 1: and (5) bacteriostatic ring experiment.
Preparing the medicine: dissolving dendrophenol by DMSO to prepare mother liquor with the concentration of 160 mg/mL. In the experiment, 4 times of sterile liquid culture medium is used for diluting the dendrophenol mother liquor to prepare the dendrophenol experiment concentration (40 mg/mL).
The experimental method comprises the following steps: measuring by agar diffusion method, taking a plate with diameter of 12 cm, adding 10 mL of culture medium, condensing, respectively dipping different bacteria solutions (Propionibacterium acnes, Staphylococcus aureus or Escherichia coli) with sterile cotton swab, uniformly coating on the surface of the culture medium, and standing at room temperature for 3-5 min. Sterile Oxford cups with a diameter of 6 mm were placed on an agar plate, 50. mu.L of dendrophenol at a concentration of 40 mg/mL was added to the cups, and DMSO (25%) was used as control wells, 3 controls were repeated for each condition. The diameter of the bacteriostatic ring is measured after culturing at 37 ℃ for 24 h.
The experimental results are as follows: as shown in figure 1, dendrophenol significantly increased the bacteriostatic ring radius of Propionibacterium acnes, Staphylococcus aureus, or Escherichia coli compared to control group (DMSO) ((R))P <0.05). The dendrophenol can obviously inhibit the in vitro growth of propionibacterium acnes, staphylococcus aureus or escherichia coli and has obvious antibacterial activity.
Example 2: minimum Inhibitory Concentration (MIC) assay.
The experimental method comprises the following steps: the liquid dilution method is used for measuring, and a culture medium control hole, a bacteria liquid control hole (propionibacterium acnes, staphylococcus aureus or escherichia coli) and a dendrophenol liquid medicine control hole are arranged in a 96-hole cell culture plate. Diluting dendrophenol (with concentration of 40 mg/mL-1.25 mg/mL) with liquid culture medium in equal times, adding 100 μ L of diluted dendrophenol liquid and 10 μ L of test bacterial liquid (Propionibacterium acnes, Staphylococcus aureus or Escherichia coli) into each well, culturing at 37 deg.C for 24 h, and detecting absorbance (OD) value of 600 nm wavelength of each well by MTT method. The critical drug concentration before the sudden increase of the OD value is taken as the Minimum Inhibitory Concentration (MIC) of the drug.
The experimental results are as follows: as shown in figure 2, the MICs of dendrophenol to Propionibacterium acnes and Escherichia coli were both 10 mg/mL, and the MICs of dendrophenol to Staphylococcus aureus were both 20 mg/mL. The results show that the dendrophenol has obvious antibacterial and bacteriostatic effects on propionibacterium acnes, staphylococcus aureus and escherichia coli.
The above embodiments are described in further detail to solve the technical problems, technical solutions and advantages of the present invention, and it should be understood that the above embodiments are only examples of the present invention and are not intended to limit the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (3)
1. Application of dendrophenol in preparing medicine for resisting Propionibacterium acnes is provided.
2. Application of dendrophenol in preparing medicine for inhibiting Staphylococcus aureus is provided.
3. Application of dendrophenol in preparing medicine for inhibiting Escherichia coli is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010794889.0A CN111773202B (en) | 2020-08-10 | 2020-08-10 | Medical application of dendrophenol and anti-propionibacterium acnes medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010794889.0A CN111773202B (en) | 2020-08-10 | 2020-08-10 | Medical application of dendrophenol and anti-propionibacterium acnes medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111773202A CN111773202A (en) | 2020-10-16 |
| CN111773202B true CN111773202B (en) | 2022-06-17 |
Family
ID=72762040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010794889.0A Active CN111773202B (en) | 2020-08-10 | 2020-08-10 | Medical application of dendrophenol and anti-propionibacterium acnes medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773202B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114903907A (en) * | 2022-05-31 | 2022-08-16 | 合肥师范学院 | Application of arenobufagin and derivatives thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140288186A1 (en) * | 2013-03-19 | 2014-09-25 | Tunghai University | Method for lowering blood glucose and method for treating hepatic disease, obesity and diabetes |
| CN107308141A (en) * | 2017-05-31 | 2017-11-03 | 合肥师范学院 | Application of the dendrophnol and combinations thereof in prevention and treatment atherosclerosis medicine is prepared |
| CN110302080A (en) * | 2019-07-24 | 2019-10-08 | 汉义生物科技（北京）有限公司 | Hemp compounds Herba Dendrobii extract and its preparation method and application |
-
2020
- 2020-08-10 CN CN202010794889.0A patent/CN111773202B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140288186A1 (en) * | 2013-03-19 | 2014-09-25 | Tunghai University | Method for lowering blood glucose and method for treating hepatic disease, obesity and diabetes |
| CN107308141A (en) * | 2017-05-31 | 2017-11-03 | 合肥师范学院 | Application of the dendrophnol and combinations thereof in prevention and treatment atherosclerosis medicine is prepared |
| CN110302080A (en) * | 2019-07-24 | 2019-10-08 | 汉义生物科技（北京）有限公司 | Hemp compounds Herba Dendrobii extract and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| Gigantol has Protective Effects against High Glucose-Evoked Nephrotoxicity in Mouse Glomerulus Mesangial Cells by Suppressing ROS/MAPK/NF-κB Signaling Pathways;Chen M et al;《Molecules》;20181226;第24卷;第80页 * |
| 叠鞘石斛水提取物对小肠结肠炎耶尔森菌的抗菌活性及机制研究;张薇薇 等;《现代预防医学》;20161231;第43卷(第10期);第1852-1854、1883页 * |
| 铁皮石斛化学成分及其药理功效研究进展;张帮磊 等;《临床医药文献电子杂志》;20191231;第6卷(第54期);第3、8页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111773202A (en) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10034842B2 (en) | Antimicrobials and methods of use thereof for wound healing | |
| THOMSEN et al. | Pustulosis palmaris et plantaris | |
| CN111494282B (en) | Red-removing anti-inflammatory oil-controlling acne-removing composition, application thereof and acne-removing balancing essence containing composition | |
| CN111773202B (en) | Medical application of dendrophenol and anti-propionibacterium acnes medicine | |
| Ahmed et al. | The influence of Egyptian propolis on induced burn wound healing in diabetic rats; antibacterial mechanism | |
| CN102614294B (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| Alsaimary | Bacterial wound infections in diabetic patients and their therapeutic implications | |
| WO2024011868A1 (en) | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis | |
| Buzia¹ et al. | Antibacterial action of certain tretinoin and benzoyl peroxide liposomes. Case study | |
| CN112675199B (en) | Drug combination and application thereof | |
| Schiavo et al. | In vitro evaluation of the antimicrobial activity of a topical skin preparation containing 0.1% polyhexanide vs a topical skin preparation containing 1% silver sulfadiazine | |
| EP3888649B1 (en) | Cannflavin a for use in promoting wound healing and treating or preventing diabetic feet | |
| RU2613708C2 (en) | Ways of acne treatment | |
| CN110215445B (en) | Application of vanillic acid in inhibiting growth of multiple drug-resistant enterobacter hopcalis | |
| US20210393520A1 (en) | Treatment of gram-negative folliculitis or an inflammation thereof with besifloxacin | |
| CN101780034B (en) | Cefathiamidine suspension and novel application thereof | |
| CN115487202B (en) | Application of fidaxomicin in preparation of medicines for resisting nocardia infection | |
| CN103006699A (en) | Compound medicament with double effects of alleviating pain and inhibiting bacteria | |
| US20030096850A1 (en) | Treating infections by administration of oxazolidinones | |
| US10398664B2 (en) | Methods of diagnosing and treating infected implants | |
| CN106974926B (en) | A kind of pharmaceutical composition and its preparation method and application for treating pressure sore | |
| Couchonnal et al. | Complications with heparin-lock needles | |
| CN1039522C (en) | Compounded painkilling and anti inflammatory cream | |
| Dhayanithi et al. | Role of Terminalia bellirica extract on uropathogens in diabetes condition. | |
| CN115715799A (en) | Composition for preventing or treating fungal infection, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Wei Inventor after: Wang Xiangcun Inventor after: Zhang Yang Inventor after: Cheng Yan Inventor after: Wang Yiyuan Inventor after: Shen Qian Inventor after: Tan Xiaohua Inventor after: Qin Shuyi Inventor after: Hu Jie Inventor before: Wang Xiangcun Inventor before: Wang Wei Inventor before: Zhang Yang Inventor before: Cheng Yan Inventor before: Wang Yiyuan Inventor before: Shen Qian Inventor before: Tan Xiaohua Inventor before: Qin Shuyi Inventor before: Hu Jie |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |